title: Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model.
abstract: BACKGROUND
  In this study, we used vidagliptin(V) to examine the role of the DDP-IV, incretin system component, in the activation of different molecular inflammatory cytokines, NF-kB and VCAM-1 to generate a microenvironment that supports cardiovascular remodeling.
  
  
  METHODS
  Male WKY and SHR were separated into five groups: Control, FFR: WKY rats receiving a 10% (w/v) fructose solution during all 12 weeks, SHR, FFHR: SHR receiving a 10% (w/v) fructose solution during all 12 weeks and FFHR+V: (5 mg/kg per day for 6 weeks) (n = 8 each group). Metabolic variables and systolic blood pressure were measured. The TBRAS, eNOS activity, and NAD(P)H oxidase activity were estimated to evaluate oxidative stress. Cardiac and vascular remodeling were evaluated. To assess the cytokine, NF-kB and VCAM-1 immunostaining techniques were used.
  
  
  RESULTS
  The FFHR experimental model presents metabolic syndrome criteria, vascular and cardiac remodeling, vascular inflammation due to increased expression of NF-kB, VCAM-1, and pro-atherogenic cytokines. Chronic treatment with V was able to reverse total or partiality of variables studied.
  
  
  CONCLUSIONS
  Data demonstrated an important effect of DDP-IV in reducing vascular inflammation, accompanied by a favorable reduction in metabolic and structural parameters.
authors.affiliation: Department of Pathology, School of Medicine, National University of Cuyo, Mendoza, Argentina; Laboratory of Cardiovascular Physiopathology, Institute of Experimental Medicine and Biology of Cuyo (IMBECU) - CONICET, Mendoza, Argentina.
authors.forename: Nicolas F
authors.initials: NF
authors.lastname: Renna
authors.affiliation: Laboratory of Cardiovascular Physiopathology, Institute of Experimental Medicine and Biology of Cuyo (IMBECU) - CONICET, Mendoza, Argentina.
authors.forename: Emiliano A
authors.initials: EA
authors.lastname: Diez
authors.affiliation: Department of Pathology, School of Medicine, National University of Cuyo, Mendoza, Argentina; Laboratory of Cardiovascular Physiopathology, Institute of Experimental Medicine and Biology of Cuyo (IMBECU) - CONICET, Mendoza, Argentina.
authors.forename: Roberto M
authors.initials: RM
authors.lastname: Miatello
mesh_terms: D000818:Animals; D001794:Blood Pressure; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage*; D005632:Fructose / Q000008:administration & dosage; D007249:Inflammation / Q000150:complications / Q000188:drug therapy*; D007333:Insulin Resistance / Q000235:genetics; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016328:NF-kappa B / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism; D014652:Vascular Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D066253:Vascular Remodeling / Q000187:drug effects
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D016328:NF-kappa B; D019010:Vascular Cell Adhesion Molecule-1; D005632:Fructose; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III